Smokers may be at a higher risk for developing hypertension, and an overactive response to normal drops in blood pressure may help explain why, according to researchers.
Researchers have developed a rapid and reliable new method to continuously monitor sickle cell disease using a microfluidics-based electrical impedance sensor. This novel technology can characterize the dynamic cell sickling and unsickling processes in sickle blood without the use of microscopic imaging or biochemical markers. The technology is being developed with the hope of providing patients with a portable, standalone sensor to conveniently self-monitor the hematological parameters of their disease and evaluate their risk of vaso-occlusion.
在芝加哥召开的美国临床肿瘤学会年会上，Mayo Clinic展示了有关结肠直肠癌早期检测以及细胞疗法对生活质量的影响的新研究。
Using a new approach that combines data from human tumors grown in mice with data from The Cancer Genome Atlas, a team led by University of Michigan Rogel Cancer Center researchers has uncovered several previously unknown biomarkers for glioblastoma, the most common malignant brain tumor. The approach could be used for other rare cancers.
In a study published in the Journal of Clinical Investigation, researchers show how the stress-responsive protein SIRT1 plays important roles in maintaining the regenerative potential of chronic myeloid leukemia leukemic stem cells and promoting leukemia development in CML.
Mayo Clinic研究人员称，规模最大的有关冒烟型多发性骨髓瘤的随机试验表明，抗癌药物来那度胺（lenalidomide）可能会延缓骨髓瘤症状的发作。这项研究由美国东部肿瘤协作组开展，由美国国家癌症研究所资助。
O maior estudo randomizado envolvendo mieloma múltiplo latente sugere que a lenalidomida, uma droga contra o câncer, pode retardar o início dos sintomas do mieloma, de acordo com pesquisadores da Mayo Clinic.
Researchers at Dana-Farber Cancer Institute and the VA Boston Healthcare System have uncovered a new vital sign for gauging survival and likelihood of having an unplanned hospitalization in older patients with blood cancers: the speed at which they can walk.In a study published today in the journal Blood, the researchers report that for every 0.
A team of researchers from Indiana University and Memorial Sloan Kettering Cancer Center have been awarded a $4.1 million National Cancer Institute “Cancer Moonshot” grant to develop immunotherapy treatments for cancer in children and adolescents, especially those with leukemia.
El mayor ensayo aleatorio para mieloma múltiple quiescente plantea que un fármaco oncológico, la lenalidomida, puede retrasar la aparición de los síntomas del mieloma, dicen los investigadores de Mayo Clinic.
Help for patients with sickle cell disease may soon come from gene editing to fix the mutation that causes the disease and boost the patient's own protective fetal hemoglobin.
The largest randomized trial involving smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of myeloma symptoms, according to Mayo Clinic researchers. The study was conducted by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute.
An international collaboration led by scientists at UT Southwestern Medical Center has identified a potential new therapeutic target for sepsis.
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.
In patients with chronic lymphocytic leukemia, the rate of disease growth is apt to follow one of three trajectories: relentlessly upward, steadily level, or something in between, scientists at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and the University of Washington report in a new study.
The cardiorespiratory fitness of survivors of childhood acute lymphoblastic leukemia is 22 per cent worse than that general Canadian population,and genetics might play a role, an UdeM researcher finds.
Forty percent of people who develop venous thromboembolism don’t know what caused it. New preclinical research further explores inflammation’s role in inciting the clots.
Scientists at Fred Hutchinson Cancer Research Center took a step toward making gene therapy more practical by simplifying the way gene-editing instructions are delivered to cells. Using a gold nanoparticle instead of an inactivated virus, they safely delivered gene-editing tools in lab models of HIV and inherited blood disorders, as reported May 27 in Nature Materials.
In his lab, UdeM professor Alexis Vallée-Bélisle is busy perfecting a biosensor that patients with kidney disease, heart disease or other chronic illnesses can use without leaving home.
Currently available evidence does not support the recent "Hour-1 Bundle" recommendation to perform five initial treatment steps within the first hour in patients with sepsis. That's the position of the European Society of Emergency Medicine (EUSEM), published in the May/June issue of the European Journal of Emergency Medicine, official journal of EUSEM. The journal is published in the Lippincott portfolio by Wolters Kluwer.
Researchers at University of California San Diego School of Medicine found higher blood pressure and pesticide exposures in children associated with a heightened pesticide spraying period around the Mother’s Day flower harvest. This study involved boys and girls living near flower crops in Ecuador.
The study will allow researchers to learn what causes the high burden of heart, lung, blood and sleep disorders in Alabama, Kentucky, Louisiana and Mississippi.
Blood donation programs represent a unique opportunity as a public health portal to screen for diseases.
UC San Diego researchers discover new role for epidermal growth factor receptor in blood stem cell development, a crucial key to being able to generate them in the laboratory, and circumvent the need for bone marrow donation.
Much like cancer, sepsis isn’t simply one condition, but rather many conditions with varying clinical characteristics that could benefit from different treatments, according to a study involving more than 100,000 patients. The findings could explain why several recent clinical trials have failed.
Scientists from Sanford Burnham Prebys have shown that a protein called BMI1 is a promising drug target for an AML subtype in which two normally separate genes, CALM and AF10, fuse together. The findings, published in Experimental Hematology, provide a rationale for evaluating a BMl1-inhibiting drug that is currently in clinical development for solid tumors.
The College of American Pathologists (CAP) introduces a streamlined testing strategy, using an algorithm to improve diagnosis of celiac disease, helping millions of Americans
Treating a stubborn blood disease that strikes children may come down to tweaking energy production in stem cells, suggests research out of West Virginia University. Wei Du, an assistant professor in the School of Pharmacy, is investigating the link between how stem cells make energy and how Fanconi anemia develops.
Below are summaries of recent Fred Hutch research, with links for additional background and media contacts.
Johns Hopkins Medicine researchers say they have developed something akin to a “Google Maps” approach for more accurately computing and visualizing the structural and functional blood vessel changes needed for tumor growth. By pairing high-quality 3D imaging data of tumor specimens from animal models with sophisticated mathematical formulas, the researchers say they now have a model that accurately represents blood traffic inside tumors, including the complex blood flow, oxygenation and structural changes that occur.
A study at The University of Texas MD Anderson Cancer Center identified a new therapeutic target in cancer cells and explains how new anti-cancer drugs called imipridones work by inducing cancer cell death in blood cancers, such as acute myeloid leukemia (AML) and mantle cell lymphoma.
BOSTON – (April 29, 2019) – Newly available results will influence the standard approach for treating diabetic macular edema in patients with good vision, thanks to a study published today in the Journal of the American Medical Association. The study was conducted by the DRCR Retina Network, a multicenter clinical research network funded by the National Eye Institute, part of the National Institutes of Health (NIH).
May is the first ever National Stop the Bleed Month, featuring training courses around the country to teach bleeding control techniques to the general public and empower them with the skills and knowledge to assist severely bleeding persons.
A monthly roundup of research briefs showcasing recent scientific advances led by Beth Israel Deaconess Medical Center faculty.
An investigational drug that may block harmful antibodies from passing through the placenta of an expectant mother to the fetus is the focus of a new clinical trial led by Kenneth Moise, MD, a maternal-fetal medicine specialist at UTHealth.
A new study examined APS at the cellular level and found that two drugs reduced development of blood clots in mice affected with the condition.
Arsenic-based therapy can reverse drug tolerance in acute myeloid leukemia, Cancer Center researchers at BIDMC show.
Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease
An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone marrow and blood disorder – for which there are no existing approved therapies.
Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) are proud to announce a five-year grant awarded by The Frederick A. DeLuca Foundation to establish The DeLuca Center for Innovation in Hematology Research.
Researchers have defined the roles of various cells in the bone marrow that are thought to control the fate of the nearly half million blood cells that develop there each day.
The loss of memory and cognitive function known to afflict survivors of septic shock is the result of a sugar that is released into the blood stream and enters the brain during the life-threatening condition.
Many people fighting a very aggressive form of acute myeloid leukemia (AML) don’t survive more than five years. These very sick patients are often unable to receive the only cure—a bone marrow transplant. Now, an international team of scientists report in Nature Cell Biology on a long-overlooked part of a leukemic cell’s internal machinery, where they may have found a key to treating the aggressive blood cancer.
A team of researchers, including a University of La Verne anthropologist, has developed a new methodology for investigating anemia and other diseases after studying a Portuguese skeletal collection dating back to the 19th and 20th centuries.
Hematology researchers have further refined how a treatment currently used urgently to control bleeding in hemophilia patients holds promise for prevention as well. A study in animals may lead to a new therapy for patients who now develop antibodies to the standard maintenance treatment.
UC San Francisco scientists have designed a large-scale screen that efficiently identifies drugs that are potent cancer-killers when combined, but only weakly effective when used alone. Using this technique, the researchers eradicated a devastating blood cancer and certain solid tumor cells by jointly administering drugs that are only partially effective when used as single-agent therapies.
ASCO, ASH, and NCCN receive letter clarifying CDC Guideline for Prescribing Opioids for Chronic Pain not meant to limit access to appropriate pain management for individuals with cancer, sickle cell disease
Precision Therapeutics Inc. today announced the completion of its merger with Helomics Holding Corporation (“Helomics”), which has become the Company’s wholly owned subsidiary, providing proprietary data- driven precision medicine solutions for women’s oncology by harnessing the knowledge gained from the patient’s own living tumor using the power of artificial intelligence (AI) technology.
Nationally renowned hematology experts will lead the Multiple Myeloma Program at NYU Langone’s Center for Blood Cancers.
Ecomed Solutions, the developer and manufacturer of innovative healthcare solutions, has created and unveiled HEMAsavR™, a new device and option for blood capture and transfer that will help medical professionals reduce costly and complex allogeneic blood transfusions.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right